Correspondence to Professor Timothy B Niewold, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, 5841 S. Maryland Ave., MC0930 Chicago, IL 60637, USA.
Ann Rheum Dis. 2013 Apr;72(4):596-601. doi: 10.1136/annrheumdis-2012-202024. Epub 2012 Aug 17.
Hyperactivity of the type I interferon (IFN) pathway is involved in the pathogenesis of systemic lupus erythematosus (SLE). Immunoglobulin like transcript (ILT3) is an immunohibitory transmembrane molecule which is induced by type I IFNs. ILT3 is expressed by plasmacytoid dendritic cells (PDCs), monocytoid dendritic cells (MDCs), and monocytes/macrophages. Given the pathogenic role of IFN in SLE, we hypothesised that the IFN-induced immunosuppressive ILT3 receptor may be dysfunctional in human SLE.
132 European-derived and 79 Hispanic-American SLE patients were genotyped for two coding-change single nucleotide polymorphisms (SNPs) predicted to interfere with protein folding in ILT3 (rs11540761 and rs1048801). 116 control DNA samples and sera from healthy controls were also studied. We detected associations between ILT3 genotype and serum cytokine profiles. ILT3 expression levels on PDCs and MDCs from 18 patients and 10 controls were studied by flow cytometry.
The rs11540761 SNP in the extracellular region was associated with decreased cell surface expression of ILT3 on circulating MDCs and to a lesser extent PDCs in SLE patients. The cytoplasmically located rs1048801 SNP was not associated with a change in dendritic cells expression of ILT3. Both SNPs were significantly and independently associated with increased levels of serum type I IFN activity in SLE patients. The rs1048801 SNP was also associated with increased serum levels of TNF-α.
Loss-of-function polymorphisms in ILT3 are associated with increased inflammatory cytokine levels in SLE, supporting a biological role for ILT3 in SLE.
I 型干扰素(IFN)途径的活性亢进参与了系统性红斑狼疮(SLE)的发病机制。免疫球蛋白样转录物(ILT3)是一种免疫抑制性跨膜分子,由 I 型 IFNs 诱导。ILT3 由浆细胞样树突状细胞(PDCs)、单核细胞样树突状细胞(MDCs)和单核细胞/巨噬细胞表达。鉴于 IFN 在 SLE 中的致病作用,我们假设 IFN 诱导的免疫抑制性 ILT3 受体在人类 SLE 中可能功能失调。
对 132 名欧洲血统和 79 名西班牙裔美国 SLE 患者进行了两种编码变化的单核苷酸多态性(SNP)的基因分型,这些 SNP 预测会干扰 ILT3 的蛋白折叠(rs11540761 和 rs1048801)。还研究了 116 个对照 DNA 样本和健康对照者的血清。我们检测了 ILT3 基因型与血清细胞因子谱之间的关联。通过流式细胞术研究了 18 名患者和 10 名对照者的 PDC 和 MDC 上的 ILT3 表达水平。
细胞外区域的 rs11540761 SNP 与 SLE 患者循环 MDC 上的细胞表面 ILT3 表达减少有关,而对 PDC 的影响较小。细胞质内的 rs1048801 SNP 与树突状细胞上 ILT3 的表达变化无关。两个 SNP 均与 SLE 患者血清 I 型 IFN 活性水平的升高显著相关且独立相关。rs1048801 SNP 还与 TNF-α 血清水平的升高相关。
ILT3 中的功能丧失多态性与 SLE 中炎症细胞因子水平的升高有关,支持 ILT3 在 SLE 中的生物学作用。